PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Boulding sold 2,812 shares of the firm’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $61.88, for a total value of $174,006.56. Following the sale, the vice president owned 105,272 shares in the company, valued at $6,514,231.36. This trade represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Elliott Boulding also recently made the following trade(s):
- On Friday, October 9th, Mark Boulding sold 192 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.26, for a total value of $12,337.92.
- On Monday, October 5th, Mark Boulding sold 1,638 shares of PTC Therapeutics stock. The stock was sold at an average price of $64.03, for a total value of $104,881.14.
- On Tuesday, October 6th, Mark Boulding sold 435 shares of PTC Therapeutics stock. The stock was sold at an average price of $64.16, for a total value of $27,909.60.
PTC Therapeutics Trading Down 3.3%
Shares of PTCT stock opened at $56.42 on Friday. PTC Therapeutics, Inc. has a 12-month low of $56.18 and a 12-month high of $90.87. The business’s 50 day moving average is $63.26 and its two-hundred day moving average is $69.87. The company has a market capitalization of $4.71 billion, a P/E ratio of -40.30, a P/E/G ratio of 4.47 and a beta of 0.52.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The firm had revenue of $357.81 million during the quarter, compared to analyst estimates of $306.43 million. PTC Therapeutics’s quarterly revenue was up 69.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.20 EPS. On average, research analysts predict that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current fiscal year.
PTC Therapeutics declared that its Board of Directors has initiated a share repurchase plan on Tuesday, November 3rd that allows the company to buy back $500 million in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase up to 9.8% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its stock is undervalued.
Analyst Ratings Changes
PTCT has been the subject of several recent analyst reports. Citigroup boosted their price target on shares of PTC Therapeutics from $108.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Barclays increased their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, August 14th. UBS Group began coverage on shares of PTC Therapeutics in a research report on Thursday, October 15th. They issued a “buy” rating and a $90.00 target price on the stock. TD Cowen lifted their target price on shares of PTC Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Finally, Truist Financial started coverage on shares of PTC Therapeutics in a research note on Friday, October 16th. They set a “hold” rating and a $62.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $99.23.
View Our Latest Analysis on PTCT
Institutional Investors Weigh In On PTC Therapeutics
Large investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its stake in shares of PTC Therapeutics by 16.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 151 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in shares of PTC Therapeutics by 1.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 13,730 shares of the biopharmaceutical company’s stock worth $1,120,000 after acquiring an additional 237 shares during the period. Allworth Financial LP raised its holdings in shares of PTC Therapeutics by 29.0% during the 3rd quarter. Allworth Financial LP now owns 1,055 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 237 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of PTC Therapeutics by 8.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,128 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 244 shares during the period. Finally, State of Wyoming boosted its position in shares of PTC Therapeutics by 15.3% during the 3rd quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 260 shares during the last quarter.
About PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Featured Articles
- Five stocks we like better than PTC Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
